AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18565884 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with less than 6 months of combined androgen suppression therapy (AST)
Number of subjects: 206
Study 16043985 — intervention group
Group type: COMPARATOR
Intervention: RDP58 100 mg
Number of subjects: 127
Study 16043985 — intervention group
Group type: COMPARATOR
Intervention: RDP58 200 mg
Number of subjects: 127
Study 16043985 — intervention group
Group type: COMPARATOR
Intervention: RDP58 300 mg
Number of subjects: 127
Study 16043985 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 127
Study 12502122 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil topical cream applied once daily for 1, 2, or 4 weeks
Number of subjects: 0
Study 12502122 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil topical cream
Number of subjects: 0
Study 12502122 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 10049964 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine sleeping position
Number of subjects: 16
Study 10049964 — intervention group
Group type: COMPARATOR
Intervention: Prone sleeping position
Number of subjects: 16
Study 7718459 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (300 mg) daily for 4 months
Number of subjects: 20
Study 7718459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet) daily for 4 months
Number of subjects: 20
Study 2381302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicalcium phosphate (129 mmol) and glucose (500 ml/10% sol)
Number of subjects: 10
Study 2381302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7287918 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (left-ear responses reinforced)
Number of subjects: 0
Study 7287918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 30911274 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 82
Study 30911274 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 82
Study 30152390 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids (prednisolone)
Number of subjects: 389
Study 30152390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 27451030 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 57
Study 27451030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 57
Study 27451030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 24387127 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized grafting
Number of subjects: 50
Study 24387127 — intervention group
Group type: COMPARATOR
Intervention: Pedicled grafting
Number of subjects: 50
Study 22527435 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/BPO 2.5% gel
Number of subjects: 797
Study 22527435 — intervention group
Group type: COMPARATOR
Intervention: Control group (Fitzpatrick skin types IV-VI)
Number of subjects: 797
Study 19438928 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10 Hz) conditioning
Number of subjects: 18
Study 19438928 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz rTMS alone
Number of subjects: 18
Study 19438928 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz rTMS in healthy controls
Number of subjects: 18
Study 19438928 — intervention group
Group type: COMPARATOR
Intervention: Sham conditioning
Number of subjects: 18
Study 18098001 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine treatment approaches
Number of subjects: 1016
Study 15606443 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim 200 mg given twice daily for 5 days
Number of subjects: 8
Study 12089223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/m2 oral topotecan with 1,000 mg GF120918
Number of subjects: 16
Study 12089223 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/m2 intravenous topotecan with 1,000 mg GF120918
Number of subjects: 16
Study 12089223 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg/m2 oral topotecan without GF120918
Number of subjects: 16
Study 12089223 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg/m2 intravenous topotecan without GF120918
Number of subjects: 16
Study 9453518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator with heparin estimated by aPTT
Number of subjects: 0
Study 9453518 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate decrease in fibrinogen
Number of subjects: 0
Study 9453518 — intervention group
Group type: EXPERIMENTAL
Intervention: Large decrease in fibrinogen
Number of subjects: 0
Study 9453518 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fibrinogen and plasminogen values at baseline
Number of subjects: 0
Study 9453518 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent monitoring of aPTT during the first 24 to 48 hours
Number of subjects: 0
Study 7822520 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine, 250 mg/day
Number of subjects: 180
Study 7822520 — intervention group
Group type: COMPARATOR
Intervention: griseofulvin, 500 mg/day
Number of subjects: 180
Study 2225640 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing in the right knee
Number of subjects: 25
Study 2225640 — intervention group
Group type: COMPARATOR
Intervention: Non-resurfacing in the left knee
Number of subjects: 25
Study 682218 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (25 gm during operation and 150 gm/day for 3 to 5 days thereafter)
Number of subjects: 52
Study 682218 — intervention group
Group type: COMPARATOR
Intervention: Non-albumin resuscitation
Number of subjects: 52
Study 30707970 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Number of subjects: 265
Study 30707970 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein treatment
Number of subjects: 265
Study 30707970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 30057104 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose PPI (40 mg twice-daily)
Number of subjects: 2557
Study 30057104 — intervention group
Group type: COMPARATOR
Intervention: Low-dose PPI (20 mg once-daily)
Number of subjects: 2557
Study 30057104 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg per day in the UK, 325 mg per day in Canada)
Number of subjects: 2557
Study 30057104 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 2557
Study 30057104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-dose PPI and aspirin
Number of subjects: 2557
Study 30057104 — intervention group
Group type: COMPARATOR
Intervention: Low-dose PPI without aspirin
Number of subjects: 2557
Study 25759177 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based oral care training programme
Number of subjects: 94
Study 25759177 — intervention group
Group type: COMPARATOR
Intervention: Routine oral care education
Number of subjects: 94
Study 24912589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 11,629) received screening, risk assessment, and lifestyle counselling up to four times over five years.
Number of subjects: 59616
Study 24912589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 11,629) received lifestyle counselling.
Number of subjects: 59616
Study 24912589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 11,629) received combined lifestyle intervention.
Number of subjects: 59616
Study 24912589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 11,629) received lifestyle intervention.
Number of subjects: 59616
Study 22354743 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (20,000 IU weekly)
Number of subjects: 68
Study 22354743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 20207618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermacyn(R) Wound Care (DWC)
Number of subjects: 40
Study 20207618 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 40
Study 18030230 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg daily for 12 months)
Number of subjects: 72
Study 18030230 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg daily for 12 months) + Vitamin D2 (50,000 IU monthly for 6 months)
Number of subjects: 72
Study 18030230 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 72
Study 16219012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg qd
Number of subjects: 279
Study 16219012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg qd
Number of subjects: 279
Study 16219012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 12802214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical treatment for chronic illnesses
Number of subjects: 0
Study 12802214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical treatment
Number of subjects: 0
Study 10778797 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy (water) at 30 degrees/s
Number of subjects: 6
Study 10778797 — intervention group
Group type: COMPARATOR
Intervention: Dry land therapy at 30 degrees/s
Number of subjects: 6
Study 10778797 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy (water) at 45 degrees/s
Number of subjects: 6
Study 10778797 — intervention group
Group type: COMPARATOR
Intervention: Dry land therapy at 45 degrees/s
Number of subjects: 6
Study 8879718 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective forms of ECT
Number of subjects: 143
Study 8879718 — intervention group
Group type: COMPARATOR
Intervention: Ineffective forms of ECT
Number of subjects: 143
Study 1537520 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg
Number of subjects: 13
Study 1537520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 6370811 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily
Number of subjects: 35
Study 6370811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6370811 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 35
Study 30105847 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical liposomal hydroquinone
Number of subjects: 20
Study 30105847 — intervention group
Group type: COMPARATOR
Intervention: Conventional hydroquinone
Number of subjects: 20
Study 27778161 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Training (AOT)
Number of subjects: 25
Study 27778161 — intervention group
Group type: COMPARATOR
Intervention: Landscape (control group)
Number of subjects: 25
Study 24957562 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-forensic family assessment (experimental group)
Number of subjects: 4629
Study 24957562 — intervention group
Group type: COMPARATOR
Intervention: Forensic investigation (control group)
Number of subjects: 4629
Study 25379688 — intervention group
Group type: EXPERIMENTAL
Intervention: Active supplement (500 mg olive leaf extract, 100 mg green coffee bean extract, 150 mg beet powder)
Number of subjects: 37
Study 25379688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22546837 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (T) 75 mg/m² on day 1 of a 21-day cycle for six cycles
Number of subjects: 100
Study 22546837 — intervention group
Group type: COMPARATOR
Intervention: Control (no docetaxel)
Number of subjects: 100
Study 19046909 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I (50 microg/kg, four days/week)
Number of subjects: 27
Study 19046909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17321927 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40
Study 17321927 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonstimulation group)
Number of subjects: 40
Study 15138163 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids plus daclizumab (1 mg/kg)
Number of subjects: 102
Study 15138163 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (2 mg/kg)
Number of subjects: 102
Study 15257932 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation (performed in 47 patients with a donor)
Number of subjects: 279
Study 15257932 — intervention group
Group type: COMPARATOR
Intervention: Autologous transplantation or maintenance chemotherapy (given to 84 patients without a sibling donor)
Number of subjects: 279
Study 15257932 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation (with donor)
Number of subjects: 279
Study 15257932 — intervention group
Group type: COMPARATOR
Intervention: Autologous transplantation or maintenance chemotherapy (without donor)
Number of subjects: 279
Study 10333984 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone (up to 160 mg single dose or 80 mg/day for 7 days)
Number of subjects: 0
Study 10333984 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone (up to 20 mg once daily)
Number of subjects: 0
Study 10333984 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone (10 mg dose)
Number of subjects: 0
Study 10333984 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone (various doses)
Number of subjects: 0
Study 10333984 — intervention group
Group type: EXPERIMENTAL
Intervention: Befloxatone
Number of subjects: 0
Study 8024805 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 0
Study 8024805 — intervention group
Group type: COMPARATOR
Intervention: Prednicarbate
Number of subjects: 0
Study 8024805 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol 17-propionate
Number of subjects: 0
Study 2654849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (7.9 +/- 0.4 mg/kg)
Number of subjects: 10
Study 2654849 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 10
Study 616218 — intervention group
Group type: EXPERIMENTAL
Intervention: CO breathing (increased COHb saturation)
Number of subjects: 44
Study 616218 — intervention group
Group type: COMPARATOR
Intervention: Air breathing (control)
Number of subjects: 44
Study 30590827 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Renal Diet (NNRD)
Number of subjects: 18
Study 30590827 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 18
Study 28369530 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg)
Number of subjects: 127
Study 28369530 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (200 μg/kg)
Number of subjects: 127
Study 28369530 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin
Number of subjects: 127
Study 28369530 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin
Number of subjects: 127
Study 28369530 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin and Ivermectin
Number of subjects: 127
Study 25700320 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture adhesives (DA)
Number of subjects: 60
Study 25700320 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture adhesives (DA) in glue form
Number of subjects: 60
Study 24485039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure (ICP) monitoring
Number of subjects: 324
Study 24485039 — intervention group
Group type: COMPARATOR
Intervention: Clinical exam-based monitoring
Number of subjects: 324
Study 20884178 — intervention group
Group type: EXPERIMENTAL
Intervention: Waon therapy
Number of subjects: 54
Study 20884178 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 54
Study 19148629 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of DHA/EPA (3.0 g/day, t.i.d. for 28 days)
Number of subjects: 48
Study 19148629 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of DHA/EPA (3.0 g/day, t.i.d. for 28 days)
Number of subjects: 48
Study 19148629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 48
Study 17529899 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg twice a day
Number of subjects: 88
Study 17529899 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 1000 mg twice a day
Number of subjects: 88
Study 17529899 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 88
Study 15061265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic and non-dopaminergic treatment (off-medication)
Number of subjects: 14
Study 15061265 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study 11447960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing resin composite (Light Bond)
Number of subjects: 45
Study 11447960 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (Fuji Ortho LC)
Number of subjects: 45
Study 11447960 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride-releasing resin composite (Concise)
Number of subjects: 45
Study 9493577 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 l gelatin‐based plasma substitute (Gelofusine)
Number of subjects: 6
Study 9493577 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control)
Number of subjects: 6
Study 8043455 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine slow infusion
Number of subjects: 42
Study 8043455 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine bolus injection
Number of subjects: 42
Study 1818430 — intervention group
Group type: EXPERIMENTAL
Intervention: Klion ointment
Number of subjects: 28
Study 1818430 — intervention group
Group type: COMPARATOR
Intervention: Control group (another method)
Number of subjects: 28
Study 76857 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection/compression sclerotherapy
Number of subjects: 100
Study 76857 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study 30901716 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise programme
Number of subjects: 120
Study 30901716 — intervention group
Group type: COMPARATOR
Intervention: Health education programme (control)
Number of subjects: 120
Study 27935240 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg once daily
Number of subjects: 100
Study 27935240 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 25452012 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal stenosis pedometer and nutrition lifestyle intervention (12 weeks)
Number of subjects: 10
Study 23566446 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 478
Study 23566446 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 478
Study 21806517 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or four counselling sessions involving cognitive behaviour therapy and motivational interviewing techniques to manage methamphetamine use.
Number of subjects: 214
Study 21806517 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet (control group).
Number of subjects: 214
Study 19013544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (FiO(2): 0.15-0.12)
Number of subjects: 18
Study 19013544 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (control)
Number of subjects: 18
Study 18257156 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy with sparfloxacine and vibromagnetolaser therapy (VMLG‐10 unit)
Number of subjects: 49
Study 18257156 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial therapy with sparfloxacine and 10 sessions of manual massage
Number of subjects: 49
Study 18257156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibromagnetolaser therapy (VMLG‐10 unit)
Number of subjects: 49
Study 15142009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench press exercise at 60% 1RM
Number of subjects: 28
Study 15142009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench press exercise at 80% 1RM
Number of subjects: 28
Study 11187872 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose FVIII regimen
Number of subjects: 0
Study 11187872 — intervention group
Group type: COMPARATOR
Intervention: Low-dose FVIII regimen
Number of subjects: 0
Study 11187872 — intervention group
Group type: COMPARATOR
Intervention: Bypass therapy (on demand)
Number of subjects: 0
Study 9183060 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth with oil contamination
Number of subjects: 0
Study 9183060 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth with oil contamination but no prophylaxis
Number of subjects: 0
Study 9183060 — intervention group
Group type: COMPARATOR
Intervention: Control (no oil contamination)
Number of subjects: 0
Study 8245359 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral vein contrast delivery
Number of subjects: 70
Study 8245359 — intervention group
Group type: COMPARATOR
Intervention: Upper extremity contrast delivery
Number of subjects: 70
Study 8245359 — intervention group
Group type: EXPERIMENTAL
Intervention: Precordial echocardiography with femoral vein contrast delivery
Number of subjects: 70
Study 2581469 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine, 1:200 000 adrenaline and dextran 150
Number of subjects: 2
Study 2581469 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine, 1:200 000 adrenaline and dextran 110
Number of subjects: 2
Study 30678354 — intervention group
Group type: EXPERIMENTAL
Intervention: Moyo (continuous monitoring)
Number of subjects: 2973
Study 30678354 — intervention group
Group type: COMPARATOR
Intervention: Doppler (intermittent monitoring)
Number of subjects: 2973
Study 29770528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at 1-week follow-up
Number of subjects: 354
Study 29770528 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool score (moderate or high)
Number of subjects: 354
Study 29770528 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated duration of LBP > 1 week
Number of subjects: 354
Study 29770528 — intervention group
Group type: COMPARATOR
Intervention: Control for age, sex, and medication received
Number of subjects: 354